We’re looking to expand and are in search of a new team member. Who is it that we’re looking for? An R&D Specialist. This person should have a degree in biology, biotechnology, pharmacology, medicine or related fields. He/she should also have experience related to aseptic cell-culture techniques. We are looking for an expert with basic knowledge regarding methods of analysis for intravital eukaryotic cells (light and fluorescence microscopy, flow cytometry).
If you’ve had any kind of documented training related to flow cytometry, experience working with clinical, infectious materials and in a lab that meets the requirements of the ISO/IEC 17025:2005 Management System – these things would be an added plus.
If you are someone who enjoys working independently, if consistent and precise is a good way to describe your style and habits, if you can not only speak but also write in English – especially on subjects related to your field of expertise – you’re exactly who we are looking for!
What is it that we expect? A thorough and detailed approach to your job, an open mind, a person who knows that it’s always impossible to learn everything about anything – and keeps trying!
Would you say you are good at multi-tasking, prioritizing and working under pressure? If so, it’s exactly you that we are looking for!
Make your mark: rekrutacja@bioceltix.com
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
ArticleIn the years to come, we are going to see a crop of biotechnology and other projects with global potential. Breakthrough innovations will not ...
Read fullParkiet: Bioceltix has been developing its own pharmaceuticals since 2016. It is also one of the first companies in Europe to complete a full EMA ...
Read fullOur company is one of six to qualify for InCredibles 2019 being organized by Sebastian Kulczyk. Incredibles is a multi-purpose program that ...
Read full
